article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Indeed, since 2014, DPD facilitatedthe publication of 42 quarterly batches and dozens of stand-alone PSGs, plus three one-off batches of PSGs updated to align with recommendations in general guidance documents ( g. , Under GDUFA III alone, DPD published 32 GDUFA guidance documents and MAPPs to ensure the successful implementation of GDUFA.

FDA 144
article thumbnail

FDA Inspections: Lesson 1 – Interviewing Employees

The FDA Law Blog

Farquhar This is the first in a series of blog posts on tips for successfully handling an FDA inspection. Much of the debate on this issue centers on whether FDA can take photographs during an inspection (see our previous blog post ). Walsh & Hyman, Phelps & McNamara, P.C. & & Douglas B.

FDA 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Reports Document FDA Review Delays: What Drugmakers Should Know Now

The FDA Law Blog

By John W.M. Claud & Michelle L. Butler Recent reductions in force (RIFs) and leadership changes at FDA are already affecting key agency functionsand as the administration plans a broader reorganization, the impact will likely grow. One area drawing increasing attention is how these changes will affect the drug development and review process.

article thumbnail

Guest Blog Post #14: Deprescribing in community pharmacy

The deprescribing.org Blog

Today we have another blog post for you. In this blog post, Amy will share her experiences with deprescribing from the community pharmacist perspective. Document, document, document. Pharmacists can partially address this issue by committing to thorough documentation practices at their own pharmacies.

article thumbnail

Unlocking Clinical Revenue from Within Your Pharmacy Workflow

PQA

This guest blog is one in a series by sponsors of the 2025 PQA Annual Meeting on unlocking clinical revenue from within pharmacy workflow. While clinical services represent the future, the practical challenge of documenting these encounters threatens to impede progress. The business of pharmacy is at a critical juncture.

article thumbnail

FDA Publishes Its Draft Strategy Document on Innovative Manufacturing Technologies

The FDA Law Blog

FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies. It was at this workshop that the agency committed to issuing a draft strategy document, for public comment.

article thumbnail

Presentation of Controlled Documents with Paperless Validation Systems

ISPE

Background In paper based CQV programs, the inspection process focuses on reports and execution binders; the reports summarize the conclusions of a specific study, and the execution binder provides the documented evidence used to support the conclusions in the report. Can you describe the audit trail features of this application?